CoChat
Sign Up
Cited by 609Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Diabetes, cardiovascular disease and the microcirculation

Open access
Strain, W. David, Paldánius, P. M.·2018·Cardiovascular Diabetology
DOI 10.1186/s12933-018-0703-2PMC PMC5905152
Open this paper in CoChat — free accountOpen PDF

Abstract

Cardiovascular disease (CVD) is the leading cause of mortality in people with type 2 diabetes mellitus (T2DM), yet a significant proportion of the disease burden cannot be accounted for by conventional cardiovascular risk factors. Hypertension occurs in majority of people with T2DM, which is substantially more frequent than would be anticipated based on general population samples. The impact of hypertension is considerably higher in people with diabetes than it is in the general population, suggesting either an increased sensitivity to its effect or a confounding underlying aetiopathogenic mechanism of hypertension associated with CVD within diabetes. In this contribution, we aim to review the changes observed in the vascular tree in people with T2DM compared to the general population, the effects of established anti-diabetes drugs on microvascular outcomes, and explore the hypotheses to account for common causalities of the increased prevalence of CVD and hypertension in people with T2DM.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-018-0703-2

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CVD remains the leading cause of mortality among diabetic patients.

    “CVD, one of the most severe systemic complications of diabetes, remains the leading cause of mortality among diabetic patients [9, 81, 82].”

    From Artificial intelligence-powered prediction of diabetic complications: from clinical data to molecular omics (2026) · cites this paper as [81]

    The Abstract states that CVD is the leading cause of mortality in people with type 2 diabetes. The citing sentence says this of diabetic patients generally, extending the claim beyond the population specified in the source. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 95

  1. [3]Chantler PD Frisbee JC Arterial function in cardio-metabolic diseases: from the microcirculation to the large conduits Prog Cardiovasc Dis 2015 57 489 496 25220256
  2. [4]Niiranen TJ Kalesan B Hamburg NM Benjamin EJ Mitchell GF Vasan RS Relative contributions of arterial stiffness and hypertension to cardiovascular disease: the Framingham Heart Study J Am Heart Assoc. 2016 5 e004271 27912210 PMC5210358
  3. [5]Bastos JM Bertoquini S Polónia J Prognostic significance of ambulatory arterial stiffness index in hypertensives followed for 8.2 years: its relation with new events and cardiovascular risk estimation Rev Port Cardiol 2010 29 1287 1303 21179973
  4. [6]Cardoso CR Ferreira MT Leite NC Salles GF Prognostic impact of aortic stiffness in high-risk type 2 diabetic patients: the Rio deJaneiro type 2 diabetes cohort study Diabetes Care 2013 36 3772 3778 23877987 PMC3816863
  5. [7]Smulyan H Lieber A Safar ME Hypertension, diabetes type II, and their association: role of arterial stiffness Am J Hypertens 2016 29 5 13 26156872
  6. [8]Natali A Toschi E Baldeweg S Ciociaro D Favilla S Saccà L Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes Diabetes 2006 55 1133 1140 16567539
  7. [9]Strain WD Chaturvedi N Dockery F Shiff R Shore AC Bulpitt CJ Increased arterial stiffness in Europeans and African Caribbeans with type 2 diabetes cannot be accounted for by conventional cardiovascular risk factors Am J Hypertens 2006 19 889 896 16942929
  8. [10]Park CM Tillin T March K Jones S Whincup PH Mayet J Adverse effect of diabetes and hyperglycaemia on arterial stiffness in Europeans, South Asians, and African Caribbeans in the SABRE study J Hypertens 2016 34 282 289 26628109 PMC4841389
  9. [11]Madonna R Balistreri CR Geng YJ De Caterina R Diabetic microangiopathy: pathogenetic insights and novel therapeutic approaches Vasc Pharmacol 2017 90 1 7 28137665
  10. [12]Stehouwer CD Ferreira I Safar M O’Rourke M Diabetes, lipids and other cardiovascular risk factors Handbook of hypertension. Arterial stiffness hypertension 2006 Edinburgh Elsevier 427 456
  11. [13]Urbina EM Khoury PR McCoy C Daniels SR Kimball TR Dolan LM Cardiac and vascular consequences of pre-hypertension in youth J Clin Hypertens 2011 13 332 342 PMC3092159 21545394
  12. [14]Tropeano AI Boutouyrie P Katsahian S Laloux B Laurent S Glucose level is a major determinant of carotid intima-media thickness in patients with hypertension and hyperglycemia J Hypertens 2004 22 2153 2160 15480100
  13. [15]Rubin J Nambi V Chambless LE Steffes MW Juraschek SP Coresh J Hyperglycemia and arterial stiffness: the atherosclerosis risk in the communities study Atherosclerosis. 2012 225 246 251 23031361 PMC3936879
  14. [16]Stirban A Gawlowski T Roden M Vascular effects of advanced glycation endproducts: clinical effects and molecular mechanisms Mol Metab. 2013 3 94 108 24634815 PMC3953708
  15. [17]Brohall G Odén A Fagerberg B Carotid artery intima-media thickness in patients with type 2 diabetes mellitus and impaired glucose tolerance: a systematic review Diabet Med 2006 23 609 616 16759301
  16. [18]Madonna R Caterina RD Cellular and molecular mechanisms of vascular injury in diabetes–part I: pathways of vascular disease in diabetes Vasc Pharmacol. 2011 54 68 74 21453786
  17. [19]Madonna R Caterina RD Cellular and molecular mechanisms of vascular injury in diabetes–part II: cellular mechanisms and therapeutic targets Vasc Pharmacol. 2011 54 75 79 21453785
  18. [20]Park SW Jun HO Kwon E Yun JW Kim JH Park YJ Antiangiogenic effect of betaine on pathologic retinal neovascularization via suppression of reactive oxygen species mediated vascular endothelial growth factor signalling Vasc Pharmacol. 2017 90 19 26 27473515
  19. [21]Monnier L Mas E Ginet C Michel F Villon L Cristol JP Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes JAMA 2006 295 1681 1687 16609090
  20. [22]Zinman B Marso SP Poulter NR Emerson SS Pieber TR Pratley RE Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2) Diabetologia 2018 61 48 57 28913575 PMC6002963
  21. [23]Su G Mi SH Tao H Li Z Yang HX Zheng H Impact of admission glycemic variability, glucose, and glycosylated hemoglobin on major adverse cardiac events after acute myocardial infarction Diabetes Care 2013 36 1026 1032 23349547 PMC3609497
  22. [24]Rizzo MR Barbieri M Marfella R Paolisso G Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition Diabetes Care 2012 35 2076 2082 22688551 PMC3447848
  23. [25]Barbieri M Rizzo MR Marfella R Boccardi V Esposito A Pansini A Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors Atherosclerosis 2013 227 349 354 23375680
  24. [26]Frisbee JC Butcher JT Frisbee SJ Olfert IM Chantler PD Tabone LE Increased peripheral vascular disease risk progressively constrains perfusion adaptability in the skeletal muscle microcirculation Am J Physiol Heart Circ Physiol. 2016 310 4 H488 H504 26702145 PMC4796615
  25. [27]de Boer RA Doehner W van der Horst IC Anker SD Babalis D Roughton M Influence of diabetes mellitus and hyperglycemia on prognosis in patients > or = 70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]) Am J Cardiol 2010 106 78 86 20609652
  26. [29]Bertoni AG Hundley WG Massing MW Bonds DE Burke GL Goff DC Jr Heart failure prevalence, incidence, and mortality in the elderly with diabetes Diabetes Care 2004 27 699 703 14988288
  27. [30]Cavallo Perin P Pacini G Giunti S Comune M Conte MR Cassader M Microvascular angina (cardiological syndrome X) per se is not associated with hyperinsulinemia or insulin resistance Eur J Clin Invest 2000 30 481 486 10849015
  28. [31]Ong P Camici PG Beltrame JF Crea F Shimokawa H Sechtem U International standardization of diagnostic criteria for microvascular angina Int J Cardiol 2018 250 16 20 29031990
  29. [32]Valenzuela-Garcia LF Matsuzawa Y Sara JD Kwon TG Lennon RJ Lerman LO Lack of correlation between the optimal glycaemic control and coronary micro vascular dysfunction in patients with diabetes mellitus: a cross sectional study Cardiovasc Diabetol. 2015 14 106 26268857 PMC4535762
  30. [33]Smits MM Tonneijck L Muskiet MH Hoekstra T Kramer MH Diamant M GLP-1-based therapies have no microvascular effects in type 2 diabetes mellitus: an acute and 12-week randomized, double-blind placebo-controlled trial Arterioscler Thromb Vasc Biol. 2016 36 2125 2132 27562916
  31. [34]Rizzoni D Agabiti Rosei E Small artery remodeling in hypertension and diabetes Curr Hypertens Rep 2006 8 90 95 16600165
  32. [35]Laurent S Boutouyrie P The structural factor of hypertension: large and small artery alterations Circ Res 2015 116 1007 1021 25767286
  33. [36]Gliemann L Buess R Nyberg M Hoppeler H Odriozola A Thaning P Capillary growth, ultrastructure remodelling and exercise training in skeletal muscle of essential hypertensive patients Acta Physiol 2015 214 210 220 25846822
  34. [37]Rizzoni D Porteri E Guelfi D Muiesan ML Valentini U Cimino A Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with non-insulin-dependent diabetes mellitus Circulation 2001 103 1238 1244 11238267
  35. [38]Schofield I Malik R Izzard A Austin C Heagerty A Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia Circulation 2002 106 3037 3043 12473548
  36. [39]Scalia R Gong Y Berzins Bc. Hyperglycemia is a major determinant of albumin permeability in diabetic microcirculation: the role of mu-calpain Diabetes 2007 56 1842 1849 17446533
  37. [40]Akerstrom T Laub L Vedel K Brand CL Pedersen BK Lindqvist AK Increased skeletal muscle capillarization enhances insulin sensitivity Am J Physiol Endocrinol Metab 2014 307 E1105 E1116 25352432
  38. [41]Strain WD Chaturvedi N Hughes A Nihoyannopoulos P Bulpitt CJ Rajkumar C Associations between cardiac target organ damage and microvascular dysfunction: the role of blood pressure J Hypertens 2010 28 952 958 20216092
  39. [42]Strain WD Chaturvedi N Bulpitt CJ Rajkumar C Shore AC Albumin excretion rate and cardiovascular risk: could the association be explained by early microvascular dysfunction? Diabetes 2005 54 1816 1822 15919804
  40. [43]Jumar A Ott C Kistner I Friedrich S Michelson G Harazny JM Early signs of end-organ damage in retinal arterioles in patients with type 2 diabetes compared to hypertensive patients Microcirculation. 2016 23 447 455 27270643
  41. [44]Levy BI Schiffrin EL Mourad JJ Agostini D Vicaut E Safar ME Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus Circulation 2008 118 968 976 18725503
  42. [45]Buus NH Bottcher M Jorgensen CG Christensen KL Thygesen K Nielsen TT Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or β-blockade in patients with essential hypertension Hypertension 2004 44 465 470 15326083
  43. [46]von Scholten BJ Rosendahl A Hasbak P Bergholdt R Kjaer A Rossing P Impaired coronary microcirculation in type 2 diabetic patients is associated with elevated circulating regulatory T cells and reduced number of IL-21R + T cells Cardiovasc Diabetol. 2016 15 67 27095356 PMC4837587
  44. [47]Strain WD Hughes AD Mayet J Wright AR Kooner J Chaturvedi N Attenuated systemic microvascular function in men with coronary artery disease is associated with angina but not explained by atherosclerosis Microcirculation. 2013 20 670 677 23682790
  45. [48]Yip W Sabanayagam C Ong PG Patel UD Chow KY Tai ES Ling LH Wong TY Cheung CY Joint effect of early microvascular damage in the eye & kidney on risk of cardiovascular events Sci Rep. 2016 6 27442 27273133 PMC4897605
  46. [49]Mathur R Bhaskaran K Edwards E Lee H Chaturvedi N Smeeth L Population trends in the 10-year incidence and prevalence of diabetic retinopathy in the UK: a cohort study in the Clinical Practice Research Datalink 2004–2014 BMJ Open 2017 7 e014444 28246144 PMC5337737
  47. [50]Guo VY Cao B Wu X Lee JJ Zee BC Prospective association between diabetic retinopathy and cardiovascular disease—a systematic review and meta-analysis of cohort studies J Stroke Cerebrovasc Dis. 2016 25 1688 1695 27068777
  48. [52]Wong TY Rosamond W Chang PP Couper DJ Sharrett AR Hubbard LD Retinopathy and risk of congestive heart failure JAMA 2005 293 63 69 15632337
  49. [53]Hafner J Ginner L Karst S Leitgeb R Unterluggauer M Sacu S Regional patterns of retinal oxygen saturation and microvascular hemodynamic parameters preceding retinopathy in patients with type II diabetes Invest Ophthalmol Vis Sci 2017 58 5541 5547 29075765
  50. [54]Liew G Wong TY Mitchell P Cheung N Wang JJ Retinopathy predicts coronary heart disease mortality Heart 2009 95 391 394 18697802
  51. [55]Forst T Michelson G Ratter F Weber MM Anders S Mitry M Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function Diabet Med 2012 29 1115 1118 22288732
  52. [56]Ott C Raff U Schmidt S Kistner I Friedrich S Bramlage P Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes Cardiovasc Diabetol. 2014 13 19 24423149 PMC3897922
  53. [57]Berndt-Zipfel C Michelson G Dworak M Mitry M Löffler A Pfützner A Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus—results from an exploratory study Cardiovasc Diabetol. 2013 12 59 23565740 PMC3637086
  54. [58]Faber R Zander M Pena A Michelsen MM Mygind ND Prescott E Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes—a randomized, single-blinded, cross-over pilot study Cardiovasc Diabetol. 2015 14 41 25896352 PMC4407869
  55. [59]Jax T Stirban A Terjung A Esmaeili H Berk A Thiemann S A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes Cardiovasc Diabetol. 2017 16 13 28109295 PMC5251248
  56. [66]Holman RR Bethel MA Mentz RJ Thompson VP Lokhnygina Y Buse JB Effects of once-weekly exenatide on cardiovascular outcomes in Type 2 diabetes N Engl J Med 2017 377 1228 1239 28910237 PMC9792409
  57. [67]Ban K Kim KH Cho CK Sauvé M Diamandis EP Backx PH Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by Exendin (9-39) yet does not require the known GLP-1 receptor Endocrinology 2010 151 1520 1531 20172966
  58. [69]Wanner C Inzucchi SE Lachin JM Fitchett D von Eynatten M Mattheus M Empagliflozin and progression of kidney disease in type 2 diabetes N Engl J Med 2016 375 323 334 27299675
  59. [70]Neal B Perkovic V Mahaffey KW de Zeeuw D Fulcher G Erondu N Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med 2017 377 644 657 28605608
  60. [71]Ott C Jumar A Striepe K Friedrich S Karg MV Bramlage P A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation Cardiovasc Diabetol. 2017 16 26 28231831 PMC5324272
  61. [72]Kim KM Jung KY Yun HM Lee SY Oh TJ Jang HC Effect of rosuvastatin on fasting and postprandial endothelial biomarker levels and microvascular reactivity in patients with type 2 diabetes and dyslipidemia: a preliminary report Cardiovasc Diabetol. 2017 16 146 29121934 PMC5679486
  62. [73]Iacobellis G Cipriani R Gabriele A Di Mario U Morano S High circulating vascular endothelial growth factor (VEGF) is related to a better systolic function in diabetic hypertensive patients Cytokine 2004 27 25 30 15207248
  63. [74]Mourad JJ des Guetz G Debbabi H Levy BI Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation Ann Oncol. 2008 19 927 934 18056916
  64. [75]Fukami M Iwase T Yamamoto K Kaneko H Yasuda S Terasaki H Changes in retinal microcirculation after intravitreal ranibizumab injection in eyes with macular edema secondary to branch retinal vein occlusion Invest Ophthalmol Vis Sci 2017 58 1246 1255 28241312
  65. [76]Svensson MK Cederholm J Eliasson B Zethelius B Gudbjörnsdottir S Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register Diab Vasc Dis Res. 2013 10 520 529 24002670
  66. [77]Wachtell K Ibsen H Olsen MH Borch-Johnsen K Lindholm LH Mogensen CE Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study Ann Intern Med 2003 139 901 906 14644892
  67. [78]Xia F Liu G Shi Y Zhang Y Impact of microalbuminuria on incident coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis of prospective studies Int J Clin Exp Med. 2015 8 1 9 25784968 PMC4358423
  68. [79]Klausen KP Scharling H Jensen JS Very low level of microalbuminuria is associated with increased risk of death in subjects with cardiovascular or cerebrovascular diseases J Intern Med 2006 260 231 237 16918820
  69. [80]Strain WD Shore AC Melzer D Albumin:creatinine ratio predicts mortality after stroke: analysis of the NHANES III J Am Geriatr Soc 2010 58 2434 2435 21143450
  70. [81]Bottcher M Madsen MM Refsgaard J Buus NH Dørup I Nielsen TT Peripheral flow response to transient arterial forearm occlusion does not reflect myocardial perfusion reserve Circulation 2001 103 1109 1114 11222474
  71. [82]Solini A Penno G Bonora E Fondelli C Orsi E Arosio M Diverging association of reduced glomerular filtration rate and albuminuria with coronary and non-coronary events in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study Diabetes Care 2012 35 143 149 22124714 PMC3241302
  72. [83]Naidoo DP The link between microalbuminuria, endothelial dysfunction and cardiovascular disease in diabetes Cardiovasc J S Afr. 2002 13 194 199 12389063
  73. [85]Haffner SM Lehto S Rönnemaa T Pyörälä K Laakso M Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 1998 339 229 234 9673301
  74. [86]Sezer M Kocaaga M Aslanger E Atici A Demirkiran A Bugra Z Bimodal pattern of coronary microvascular involvement in diabetes mellitus J Am Heart Assoc. 2016 5 11 e003995 27930353 PMC5210326
  75. [87]El-Asrar MA Andrawes NG Ismail EA Salem SM Kallistatin as a marker of microvascular complications in children and adolescents with type 1 diabetes mellitus: relation to carotid intima media thickness Vasc Med. 2015 20 509 517 26091968
  76. [88]Hannemann MM Liddell WG Shore AC Clark PM Tooke JE Vascular function in women with previous gestational diabetes mellitus J Vasc Res 2002 39 311 319 12187121
  77. [89]Jaap AJ Hammersley MS Shore AC Tooke JE Reduced microvascular hyperaemia in subjects at risk of developing type 2 (non-insulin-dependent) diabetes mellitus Diabetologia 1994 37 214 216 8163058
  78. [90]Hsu PC Liao PY Chang HH Chiang JY Huang YC Lo LC Nailfold capillary abnormalities are associated with type 2 diabetes progression and correlated with peripheral neuropathy Medicine 2016 95 e5714 28033273 PMC5207569
  79. [91]Jaap AJ Pym CA Seamark C Shore AC Tooke JE Microvascular function in type 2 (non-insulin-dependent) diabetes: improved vasodilation after one year of good glycaemic control Diabet Med 1995 12 1086 1091 8750218
  80. [92]Caballero AE Arora S Saouaf R Lim SC Smakowski P Park JY Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes Diabetes 1999 48 1856 1862 10480619
  81. [93]Jonasson H Bergstrand S Nystrom FH Länne T Östgren CJ Bjarnegård N Skin microvascular endothelial dysfunction is associated with type 2 diabetes independently of microalbuminuria and arterial stiffness Diab Vasc Dis Res. 2017 14 363 371 28482676
  82. [94]Casanova F Adingupu DD Adams F Gooding KM Looker HC Aizawa K The impact of cardiovascular co-morbidities and duration of diabetes on the association between microvascular function and glycaemic control Cardiovasc Diabetol. 2017 16 114 28915818 PMC5603035
  83. [95]Vinik AI Stansberry KB Barlow PM Rosiglitazone treatment increases nitric oxide production in human peripheral skin: a controlled clinical trial in patients with type 2 diabetes mellitus J Diabetes Complications 2003 17 279 285 12954157
  84. [96]Ijzerman RG de Jongh RT Beijk MA van Weissenbruch MM Delemarre-van de Waal HA Serné EH Individuals at increased coronary heart disease risk are characterized by an impaired microvascular function in skin Eur J Clin Invest 2003 33 536 542 12814388
  85. [97]Strain WD Hughes AD Mayet J Wright AR Kooner J Chaturvedi N Attenuation of microvascular function in those with cardiovascular disease is similar in patients of Indian Asian and European descent BMC Cardiovasc Disord. 2010 10 3 20078879 PMC2823616
  86. [98]Östlund Papadogeorgos N Jörneskog G Bengtsson M Kahan T Kalani M Severely impaired microvascular reactivity in diabetic patients with an acute coronary syndrome Cardiovasc Diabetol. 2016 15 66 27095564 PMC4837627
  87. [99]Rathsman B Jensen-Urstad K Nyström T Intensified insulin treatment is associated with improvement in skin microcirculation and ischaemic foot ulcer in patients with type 1 diabetes mellitus: a long-term follow-up study Diabetologia 2014 57 1703 1710 24802206
  88. [101]Strain WD Chaturvedi N Leggetter S Nihoyannopoulos P Bulpitt CJ Rajkumar C Ethnic differences in skin microvascular function and their relation to cardiac target-organ damage J Hypertens 2005 23 133 140 15643135
  89. [102]Strain WD Chaturvedi N Nihoyannopoulos P Bulpitt CJ Rajkumar C Shore AC Differences in the association between type 2 diabetes and impaired microvascular function among Europeans and African Caribbeans Diabetologia 2005 48 2269 2277 16193289
  90. [103]Lucas J Schiller J Benson V Summary health statistics for US adults: National Health Interview Survey, 2001. National Center for Health Statistics Vital Health Stat. 2004 2004 10 1 134 15791758
  91. [104]Harris MI Klein R Cowie CC Rowland M Byrd-Holt DD Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? A US population study Diabetes Care 1998 21 1230 1235 9702425
  92. [105]Wong TY Klein R Sharrett AR Couper DJ Klein BE Liao DP Cerebral white matter lesions, retinopathy, and incident clinical stroke JAMA 2002 288 67 74 12090864
  93. [106]Fuchs D Dupon PP Schaap LA Draijer R The association between diabetes and dermal microvascular dysfunction non-invasively assessed by laser Doppler with local thermal hyperemia: a systematic review with meta-analysis Cardiovasc Diabetol. 2017 16 11 28103890 PMC5244618
  94. [107]Clough GF Kuliga KZ Chipperfield AJ Flow motion dynamics of microvascular blood flow and oxygenation: Evidence of adaptive changes in obesity and type 2 diabetes mellitus/insulin resistance Microcirculation. 2017 27809397
  95. [108]de Jong PE Hillege HL Pinto-Sietsma SJ de Zeeuw D Screening for microalbuminuria in the general population: a tool to detect subjects at risk for progressive renal failure in an early phase? Nephrol Dial Transplant 2003 18 10 13 12480951

Cited by

Sorted by citations

Authors
Strain, W. D., & Paldánius, P. M.
Affiliations
  • University of Exeter (GB)
  • Novartis (Switzerland) (CH)
Corresponding author
Strain, W. David
ORCID
Venue
Cardiovascular Diabetology
Publisher
Springer Science and Business Media LLC
Published
2018-04-18
Volume
17
Issue
1
Pages
57-57
ISSN
1475-2840 (ISSN-L)
DOI
10.1186/s12933-018-0703-2
PMC
PMC5905152
OpenAlex
W2800981650
Cited by
609
References
9
Citations by year
2026: 49 · 2025: 83 · 2024: 119 · 2023: 103 · 2022: 92 · 2021: 85 · 2020: 60 · 2019: 15 · 2018: 3
FWCI
6.27
Type
journal article
Language
en
Update notices
correction (2021-06-11)
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Open Research Exeter (University of Exeter) (submittedVersion, cc-by)
  • Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion, cc-by)
Funders
Novartis Pharma AG
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
type 2 diabetes, cardiovascular disease, hypertension, microcirculation, vascular changes, antidiabetic drugs, microvascular outcomes, cardiovascular risk factors
MeSH terms
Animals, Cardiovascular System, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Humans, Hypertension, Hypoglycemic Agents, Microcirculation, Risk Factors, Prevalence, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review